Drug Landscape ›
ISATUXIMAB ›
Regulatory · United States
Marketing authorisation
FDA
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
Window: 20 April 2025 – 20 April 2026
Total reports: 2,593
Most-reported reactions
Neutropenia — 443 reports (17.08%) Pneumonia — 327 reports (12.61%) Plasma Cell Myeloma — 312 reports (12.03%) Covid-19 — 270 reports (10.41%) Thrombocytopenia — 255 reports (9.83%) Anaemia — 226 reports (8.72%) Pyrexia — 221 reports (8.52%) Infusion Related Reaction — 197 reports (7.6%) Diarrhoea — 192 reports (7.4%) Off Label Use — 150 reports (5.78%)
Source database →
ISATUXIMAB in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Frequently asked questions
Is ISATUXIMAB approved in United States?
Yes. FDA has authorised it.
Who is the marketing authorisation holder for ISATUXIMAB in United States?
Marketing authorisation holder not available in our data.